Dosing accuracy with a novel pen device (SoloSTAR®) as performed by patients with diabetes in a clinical setting

Diabetes Technology and Therapeutics

Volumn 10, Issue 4, 2008, Pages 322-327

  Hermanns, Norbert ^a   Kulzer, Bernhard ^a   Haak, Thomas ^a  

^a FIDAM GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; INSULIN GLULISINE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 50049095404     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0035     Document Type: Article

References (17)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
3. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV: Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-2545.
4. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Wadjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y: Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998;41:15-23.
5. Stockl K, Ory C, Vanderplas A, Nicklasson L, Lyness W, Cobden D, Chang E: An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007;23:133-146.
6. Fox C, McKinnon C, Wall A, Lawton SA: Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int 2002;19:104-107.
7. Gnanalingham MG, Newland P, Smith CP: Accuracy and reproducibility of low dose insulin administration using peninjectors and syringes. Arch Dis Child 1998;79:59-62.
8. Korytkowski M, Bell D, Jacobsen C, Suwannasari R: A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
9. Rubin RR, Peyrot M: Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2007;31:430-432.
10. Graff MR, McClanahan MA: Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998;20:486-496.
11. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL: Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725.
12. Austin F, Cox G: Lantus SoloStar and Apidra SoloStar pen colors contributes to the differentiation by users with normal vision and by users with impaired color vision. J Diabetes Sci Technol 2007;1(Suppl 1):A4.
13. Clarke A, Spollett G: Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4:165-174.
14. Pen-Injectors for Medical Use - Part 1: Pen-Injectors - Requirements and Test Methods (ISO 11608-1:2000). Geneva: International Organization for Standardization, 2000.
15. Schwartz SL, Vlajnic A: Validation of the SoloStar insulin pen [abstract]. J Diabetes Sci Technol 2007;1(Suppl 1):A159.
16. Haak T, Edelman S, Walter C, Lecointre B, Spollett G: Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29:650-660.
17. Roberts A, Thornley S: Health care professional-reported usability of SoloStar in a 3-month observational survey in everyday clinical practice. J Diabetes Sci Technol 2007;1(Suppl 1):A151.